Cytokinetics stock gains 2.15 percent as analysts target USD 109.90

Cytokinetics stock was trading at USD 66.05 on Nasdaq on September 28, 2026, up USD 1.39 or 2.15 percent from the prior close. The move comes as investors weigh strong early commercial data for Myqorzo against continuing development and regulatory risk in the company's cardiovascular pipeline.

Myqorzo drives quarterly growth

According to Seeking Alpha on September 14, 2026, Myqorzo sales rose 427.1 percent quarter over quarter to USD 25.3 million in the second quarter of 2026. The same analysis reported revenue growth of 47.8 percent quarter over quarter to USD 28.6 million.

The revenue result gives CYTK a quantified commercial anchor: second-quarter sales were USD 9.27 million higher than the first quarter's USD 19.36 million. The company is still operating at a loss, with second-quarter consolidated net loss of USD 198.76 million and diluted EPS of negative USD 1.50.

Analysts see further upside

Investing.com reported on September 1, 2026, that Truist Securities reiterated a Buy rating and a USD 112.00 price target. The report also said Barclays raised its target to USD 110.00 and Citizens lifted its target to USD 110.00 after the second-quarter results.

Investing.com lists an average 12-month analyst price target of USD 109.90, with estimates ranging from USD 85.00 to USD 146.00. Relative to the USD 66.05 intraday price, the average target is 66.39 percent higher, while the Truist target is 69.57 percent higher.

Regulatory milestone stays ahead

In its September 14, 2026 release, Cytokinetics said it plans to submit a supplemental New Drug Application in the fourth quarter of 2026 for aficamten in non-obstructive hypertrophic cardiomyopathy. That regulatory step is the next major business milestone after the product's launch in obstructive HCM.

The commercial figures are encouraging, but the risk profile remains visible in clinical data. Seeking Alpha cited reversible reductions in left-ventricular ejection fraction below 50 percent in 10.5 percent of aficamten patients versus 0.8 percent for placebo in the ACACIA-HCM study.

CYTK trades below yearly high

Cytokinetics stock was trading at USD 66.05 on Nasdaq at 3:24 p.m. ET on September 28, 2026. The session range was USD 64.40 to USD 66.30, the 52-week range was USD 50.15 to USD 88.31, market capitalization was USD 8.2 billion, and volume was 1,490,215 shares.